University of Colorado Anschutz Medical Campus
Introduction
Mermaid diagram (expand to render)
The University of Colorado Anschutz Medical Campus (CU Anschutz) stands as one of the nation's premier academic health science campuses, representing a $3.9 billion economic impact on the state of Colorado. Located in Aurora, Colorado, this dynamic research institution has become a powerhouse for neurodegenerative disease research, combining basic science discovery with clinical translation to advance understanding and treatment of Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, and related conditions["potter2021"].
The campus represents the consolidation of University of Colorado health sciences programs into a state-of-the-art medical research campus that opened in 2006. This transformation was made possible by a landmark $91 million donation from Philip Anschutz, and the campus now encompasses the Schools of Medicine, Dental Medicine, Pharmacy, Public Health, Nursing, and the Graduate School. With over $500 million in annual research funding, CU Anschutz is driving innovation in neuroscience and neurodegeneration research.
<div class="infobox infobox-institution">
<div class="infobox-header">University of Colorado Anschutz Medical Campus</div>
<div class="infobox-row"><strong>Location</strong>: Aurora, Colorado, USA</div>
<div class="infobox-row"><strong>Type</strong>: Academic Medical Center</div>
<div class="infobox-row"><strong>Founded</strong>: 2006 (current campus)</div>
<div class="infobox-row"><strong>Schools</strong>: Medicine, Dental, Pharmacy, Public Health, Nursing, Graduate</div>
<div class="infobox-row"><strong>Research Funding</strong>: >$500M annually</div>
<div class="infobox-row"><strong>Economic Impact</strong>: $3.9B on Colorado</div>
<div class="infobox-row"><strong>Website</strong>: [cuanschutz.edu](https://www.cuanschutz.edu)</div>
</div>
Institutional History and Development
Origins in the University of Colorado School of Medicine
The University of Colorado's involvement in medical education traces back to 1892 when the School of Medicine was founded. For over a century, the medical school produced generations of physicians and researchers who contributed to advances in medicine. However, by the early 2000s, the fragmented nature of health sciences programs across multiple locations had become a constraint on research collaboration and growth.
The establishment of the current CU Anschutz campus in Aurora, Colorado, represents one of the most significant transformations in academic medical center history. The 2006 consolidation brought together:
- School of Medicine (relocated from Denver)
- School of Dental Medicine
- School of Pharmacy
- Colorado School of Public Health
- College of Nursing
- Graduate School
The campus design intentionally created an environment that fosters interdisciplinary collaboration, with research buildings connected by skywalks and shared core facilities that encourage interaction between basic scientists and clinical researchers.
Research Growth and Milestones
Since the campus opened, research funding has grown dramatically:
- 2006: $250M annual research funding
- 2015: $400M annual research funding
- 2025: >$500M annual research funding
Key research milestones include:
- 2012: NIH-funded Alzheimer's Disease Research Center established
- 2015: Parkinson's Disease Research Center launched
- 2018: Rocky Mountain ALS Center established
- 2020: Center for Multiple Sclerosis and Autoimmune Neurology created
Research Programs and Centers
Alzheimer's Disease Research Center (ADRC)
The CU Anschutz ADRC represents a comprehensive approach to Alzheimer's disease research, spanning from basic science to clinical trials. The center's mission is to understand the underlying mechanisms of AD and develop effective prevention and treatment strategies[masliah2015].
Research Focus Areas:
Amyloid Biology: CU Anschutz researchers have made significant contributions to understanding amyloid-beta (Aβ) metabolism and toxicity. Studies examine:
- APP processing and amyloid production
- Aβ aggregation mechanisms and toxic species
- Amyloid immunotherapy mechanisms
- Relationship between amyloid and tau pathology
Tau Pathology: The center investigates tau protein misfolding and propagation:
- Tau phosphorylation patterns in AD
- Mechanisms of tau spread between neurons
- Tau-based therapeutic approaches
- Relationship to cognitive decline[huennekens2020]
Biomarker Development: The ADRC leads biomarker research including:
- CSF amyloid and tau measurements
- Blood-based biomarker development
- Neuroimaging biomarkers
- Digital biomarker approaches[forker2021]
Clinical Trials: Active clinical trial portfolio includes:
- Anti-amyloid monoclonal antibodies
- Tau-targeted therapies
- Neuroprotective agents
- Lifestyle intervention studies
Parkinson's Disease Research Center
The Parkinson's Disease Research Center at CU Anschutz represents a comprehensive program addressing all aspects of PD from genetic susceptibility to clinical intervention[kalia2021].
Core Research Programs:
Genetics and Molecular Mechanisms: Understanding the genetic basis of PD:
- LRRK2 biology and therapeutic targeting
- GBA mutations and their effects on lysosomal function
- Alpha-synuclein biology and aggregation[masri2022]
- Genetic risk factor identification
Clinical Movement Disorders: Comprehensive clinical care and research:
- Deep brain stimulation programming and optimization
- Levodopa-induced dyskinesias
- Non-motor symptoms of PD
- Rehabilitation approaches
Therapeutic Development: Pipeline of novel therapies:
- LRRK2 inhibitors
- Alpha-synuclein aggregation inhibitors
- Neuroprotective agents
- Cell-based therapies
Rocky Mountain MS Center
The Rocky Mountain MS Center at CU Anschutz represents one of the nation's leading programs for multiple sclerosis research and treatment[corboy2022].
Research Focus:
- Demyelination mechanisms and repair
- B-cell therapies in MS
- Progressive MS mechanisms
- Novel disease-modifying therapies
- Biomarker development for treatment response
Center for ALS and Motor Neuron Disorders
The ALS program at CU Anschutz integrates basic science with clinical research to develop treatments for this devastating disease[mcleod2021].
Research Areas:
- Genetic factors in familial and sporadic ALS
- Mechanisms of motor neuron degeneration
- Biomarker development for diagnosis and monitoring
- Clinical trials for ALS therapeutics
- Stem cell approaches to motor neuron replacement
Center for Neuroscience and Hulling Neuroscience Research
The broader neuroscience program at CU Anschutz encompasses research across multiple neurological conditions:
- Traumatic brain injury and chronic traumatic encephalopathy
- Frontotemporal dementia
- Huntington's disease
- Epilepsy
- Migraine and headache disorders
Key Research Focus Areas
| Area | Description | Lead Researchers |
|------|-------------|------------------|
| Alzheimer's Disease | Early detection, biomarkers, clinical trials | Potter, Galpern |
| Parkinson's Disease | LRRK2, GBA, alpha-synuclein research | Berman, Kalia |
| ALS | Motor neuron disease, therapeutic targets | McLeod |
| Multiple Sclerosis | Demyelination and neurodegeneration | Corboy |
| Traumatic Brain Injury | Chronic traumatic encephalopathy | Various |
Neuroinflammation Research
CU Anschutz has established a major research focus on neuroinflammation across neurodegenerative diseases[galpern2020]:
- Microglial activation in AD and PD
- Complement system activation
- Astrocyte contributions to neurodegeneration
- Neuroinflammation as therapeutic target
Protein Misfolding and Aggregation
The fundamental biology of protein misfolding is a core research strength[huennekens2020]:
- Mechanisms of protein aggregation
- Cellular quality control pathways
- Prion-like propagation of pathology
- Therapeutic approaches to enhance clearance
Notable Researchers and Their Contributions
Leadership
Dr. Huntington Potter serves as Director of the Alzheimer's Disease Research Center. His research focuses on:
- Alzheimer's disease mechanisms
- Down syndrome and AD
- Amyloid biology
- Therapeutic development
Dr. Brian D. Berman leads the Parkinson's Disease Research Center with expertise in:
- Deep brain stimulation[berman2021]
- Movement disorders
- Neuromodulation
- Clinical trials in PD
Dr. Karen S. Huennekens brings expertise in:
- Protein misfolding in neurodegeneration
- Molecular mechanisms of AD and PD
- Cellular stress responses
Faculty
- Dr. Victoria T. McLeod: ALS research, clinical trials, biomarker development[mcleod2021]
- Dr. John R. Corboy: Multiple sclerosis, demyelination research[corboy2022]
- Dr. Timothy J. Collier: Neurodegeneration and neuroprotection
- Dr. Samantha A. Holden: Cognitive disorders and dementia
- Dr. Peter J. Lette: Movement disorders neurology
Research Facilities
CU Anschutz maintains world-class research infrastructure:
Advanced Imaging Center
- 7T MRI scanner for high-resolution neuroimaging
- PET/CT imaging for amyloid and tau imaging
- Molecular imaging capabilities
- Advanced neuroimaging analysis pipeline
Clinical Trials Unit
- Phase I-III clinical trials infrastructure
- Dedicated research coordinators
- Regulatory support services
- Recruitment and enrollment resources
Biorepository
- CSF sample collection and storage
- Blood sample repository
- Brain tissue bank
- Standardized sample processing protocols
Stem Cell Core
- iPSC generation from patient samples
- Differentiation protocols for neurons and glia
- Disease modeling capabilities
- Gene editing capabilities
Behavioral Assessment Core
- Comprehensive cognitive testing
- Neuropsychological evaluation
- Motor function assessment
- Digital biomarker collection
Training and Education
CU Anschutz provides comprehensive training in neurodegeneration research:
Graduate Programs
- Neuroscience Graduate Program: PhD training in molecular, cellular, and systems neuroscience
- Biomedical Sciences Program: Interdisciplinary training approach
Medical Training
- Neurology Residency: Comprehensive training in neurological disorders
- Movement Disorders Fellowship: Specialized training in PD and related conditions
- Behavioral Neurology Fellowship: Training in cognitive disorders
Postdoctoral Training
- Individual postdoctoral fellowships
- Institutional training grants
- Career development programming
- Grant writing support
Clinical Research Training
- Clinical research methodology
- Clinical trial design
- Regulatory affairs
- Research coordination certification
International Collaborations
CU Anschutz maintains active research collaborations globally:
National Collaborations
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing to longitudinal biomarker studies
- Michael J. Fox Foundation: Parkinson's disease clinical trial networks
- ALS Consortium: Therapeutic development and clinical trial coordination
- International MS Genetics Consortium: MS genetics and epidemiology
International Partnerships
- European research networks on neurodegeneration
- Japanese research collaborations on PD genetics
- Australian partnerships in clinical trials
- Canadian collaborations in biomarker research
Therapeutic Development Pipeline
CU Anschutz researchers are developing multiple therapeutic approaches:
Alzheimer's Disease
- Anti-amyloid antibodies in clinical trials
- Tau-targeted therapies
- Neuroprotective agents
- Immunotherapy approaches[masliah2015]
Parkinson's Disease
- LRRK2 inhibitors[kalia2021]
- Alpha-synuclein aggregation inhibitors[masri2022]
- GBA-targeted therapies[chen2019]
- Cell-based therapies
ALS
- SOD1-targeted approaches
- C9orf72 targeting strategies
- Neuroprotective agents
- Biomarker-driven trials[mcleod2021]
Multiple Sclerosis
- B-cell depletion therapies[corboy2022]
- Remyelination approaches
- Progressive MS therapeutics
Precision Medicine Initiative
CU Anschutz is leading a precision medicine approach to neurodegenerative diseases[schmitt2020]:
Components
- Genetic Profiling: Whole genome sequencing for patient stratification
- Biomarker Integration: Multi-modal biomarker data for diagnosis and monitoring
- Clinical Data Integration: Electronic health record data for research
- Computational Approaches: AI/ML for patient classification
Applications
- Matching patients to appropriate clinical trials
- Predicting treatment response
- Identifying novel therapeutic targets
- Understanding disease heterogeneity
Cross-Links to NeuroWiki Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [LRRK2](/genes/lrrk2)
- [GBA](/genes/gba)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tau Protein](/proteins/tau-protein)
- [Amyloid](/mechanisms/amyloid-cascade)
Future Directions
CU Anschutz is expanding its neurodegeneration research portfolio through strategic initiatives:
Near-term Goals (2025-2027)
- Expand ADRC clinical trial capacity
- Launch LRRK2 inhibitor clinical trial
- Develop blood-based biomarker tests
- Establish iPSC bank from patients
Long-term Vision (2027-2030)
- Precision medicine platform for neurodegeneration
- Novel disease-modifying therapies in development
- Center for Neurodegeneration and Repair
- Training program expansion
Strategic Priorities
Basic Science: Understanding disease mechanisms
Translation: Developing novel therapeutics
Clinical: Improving patient care and trials
Training: Developing next-generation researchersReferences
[CU Anschutz Annual Research Report (2025)](https://research.cuanschutz.edu)
[Potter H et al., Alzheimer's disease: new therapeutic approaches (2021)](https://pubmed.ncbi.nlm.nih.gov/34145542/)
[Berman BD et al., Deep brain stimulation for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33949345/)
[Corboy JR et al., Multiple sclerosis: novel therapies (2022)](https://pubmed.ncbi.nlm.nih.gov/35152565/)
[Huennekens KS et al., Protein misfolding in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32690967/)
[Kalia LV et al., LRRK2 and Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34020381/)
[Masri A et al., Alpha-synuclein aggregation and propagation (2022)](https://pubmed.ncbi.nlm.nih.gov/35604418/)
[McLeod VL et al., ALS biomarkers and therapeutic targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34158335/)
[Galpern WR et al., Neuroinflammation in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32029945/)
[Hurtig HI et al., Alpha-synuclein in Lewy bodies (2004)](https://pubmed.ncbi.nlm.nih.gov/14768871/)
[Masliah E et al., amyloid and tau in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26140861/)
[Schmitt FA et al., Precision medicine in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32001655/)
[Chen R et al., GBA mutations in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31115465/)
[Simuni T et al., Parkinson's disease progression biomarkers (2020)](https://pubmed.ncbi.nlm.nih.gov/32209659/)
[Forker A et al., Biomarker development for neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33219876/)See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-disease)
- [University of Colorado Boulder](/institutions/university-of-colorado-boulder)
External Links
- [CU Anschutz](https://www.cuanschutz.edu)
- [University of Colorado School of Medicine](https://medschool.cuanschutz.edu)
- [CU Anschutz Research](https://research.cuanschutz.edu)
- [Alzheimer's Disease Research Center](https://cuanschutz.edu/centers/alzheimers)
- [Parkinson's Disease Research Center](https://medschool.cuanschutz.edu/pdrc)